NasdaqGM - Nasdaq Real Time Price
USD
ANI Pharmaceuticals, Inc. (ANIP)
72.83
-0.68
(-0.93%)
At close: August 28 at 4:00:01 PM EDT
72.83
0.00
(0.00%)
After hours: August 28 at 7:30:05 PM EDT
Trade ANIP on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for ANIP
Chart does not reflect overnight price.
- Previous Close
73.51 - Open
73.23 - Bid 56.91 x 200
- Ask 103.53 x 200
- Day's Range
72.61 - 73.93 - 52 Week Range
70.15 - 99.50 - Volume
360,969 - Avg. Volume
342,531 - Market Cap (intraday)
1.673B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
15.87 - EPS (TTM)
4.59 - Earnings Date (est.) Nov 6, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
108.38
Recent News
View More
Performance Overview
Trailing total returns as of 8/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ANIP
7.74%
S&P 500 (^GSPC)
12.65%
1-Year Return
ANIP
21.29%
S&P 500 (^GSPC)
18.61%
3-Year Return
ANIP
16.06%
S&P 500 (^GSPC)
73.95%
5-Year Return
ANIP
160.48%
S&P 500 (^GSPC)
71.02%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 8/27/2026
-
Market Cap
1.69B
-
Enterprise Value
1.92B
-
Trailing P/E
16.03
-
Forward P/E
8.35
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
1.66
-
Price/Book (mrq)
2.83
-
Enterprise Value/Revenue
1.97
-
Enterprise Value/EBITDA
7.86
Financial Highlights
Profitability and Income Statement
-
Profit Margin
11.07%
-
Return on Assets (ttm)
5.45%
-
Return on Equity (ttm)
20.46%
-
Revenue (ttm)
978.38M
-
Net Income Avi to Common (ttm)
99.6M
-
Diluted EPS (ttm)
4.59
Balance Sheet and Cash Flow
-
Total Cash (mrq)
376.96M
-
Total Debt/Equity (mrq)
104.82%
-
Levered Free Cash Flow (ttm)
132.21M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
72.83
-0.93%
Mkt Cap
1.673B
Industry
Drug Manufacturers—Specialty & Generic
0.2500
0.00%
Mkt Cap
3.289M
Industry
Drug Manufacturers—Specialty & Generic
25.35
-4.12%
Mkt Cap
785.83M
Industry
Drug Manufacturers—Specialty & Generic
25.76
-0.27%
Mkt Cap
1.014B
Industry
Drug Manufacturers—Specialty & Generic
34.74
-6.56%
Mkt Cap
3.871B
Industry
Drug Manufacturers—Specialty & Generic
17.54
-2.61%
Mkt Cap
6.109B
Industry
Drug Manufacturers—Specialty & Generic
2.2500
+0.45%
Mkt Cap
24.15M
Industry
Drug Manufacturers—Specialty & Generic
34.87
-1.22%
Mkt Cap
4.115B
Industry
Drug Manufacturers—Specialty & Generic
78.08
-2.16%
Mkt Cap
6.007B
Industry
Drug Manufacturers—Specialty & Generic
4.1300
-2.59%
Mkt Cap
682.441M
Industry
Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View More-
Lowering target price to $72.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Raising target price to $73.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Lowering target price to $71.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target -
Lowering target price to $75.00
ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target
